Stroke RSS

Filtered By:
Drug: Warfarin
Countries: Australia Health

This page shows you your search results in order of date.

Order by Relevance | Date

Total 14 results found since Jan 2013.

Oral Anticoagulant Use in Patients With Atrial Fibrillation and Chronic Kidney Disease: A Review of the Evidence With Recommendations for Australian Clinical Practice
Chronic kidney disease is common in patients with atrial fibrillation (AF) and is associated with heightened risks of stroke/systemic embolisation and bleeding. In this review we outline the evidence for AF stroke prevention in kidney disease, identify current knowledge gaps, and give recommendations for anticoagulation at various stages of chronic kidney disease.Overall, anticoagulation is underused. Warfarin use becomes increasingly difficult with advancing kidney disease, with difficulty maintaining international normalised ratio (INR) in therapeutic range, increased risk of intracranial and fatal bleeding compared to n...
Source: Heart, Lung and Circulation - November 3, 2022 Category: Cardiology Authors: Christopher Hammett, Sunil V. Badve, Peter G. Kerr, Huyen A. Tran, Benjamin K. Dundon, Sidney Lo, Andrew Wong, Joanne E. Joseph, Jenny Deague, Vlado Perkovic Tags: Review Source Type: research

Commentary: The case for a comprehensive clinical, basic, and translational research strategy to understand, prevent, detect, and treat cerebrovascular injury in Fontan patients
In this issue of the Journal, the Australian and New-Zealand Fontan Registry Research group compares long-term rates of cerebrovascular injury, thrombosis, bleeding, bone mineral density, and quality of life in Fontan patients receiving warfarin and those receiving aspirin.1 Their take-home messages are (1) asymptomatic cerebrovascular injury is a frequent occurrence in Fontan patients, including stroke (39%), microhemorrhage (96%), and white matter injury (86%); (2) warfarin does not seem to protect against the risk of cerebrovascular injury when compared with aspirin; and (3) warfarin is associated with a greater risk of...
Source: The Journal of Thoracic and Cardiovascular Surgery - January 19, 2021 Category: Cardiovascular & Thoracic Surgery Authors: David Kalfa Tags: Commentary Source Type: research

Quality of Warfarin Anticoagulation in Indigenous and Non-Indigenous Australians With Atrial Fibrillation
Studies have shown that suboptimal anticoagulation quality, as measured by time in therapeutic range (TTR), affects a significant percentage of patients with atrial fibrillation (AF). However, TTR has not been previously characterised in Indigenous Australians who experience a greater burden of AF and stroke.
Source: Heart, Lung and Circulation - November 27, 2019 Category: Cardiology Authors: Mau T. Nguyen, Celine Gallagher, Bradley M. Pitman, Mehrdad Emami, Kadhim Kadhim, Jeroen M. Hendriks, Melissa E. Middeldorp, Kurt C. Roberts-Thomson, Rajiv Mahajan, Dennis H. Lau, Prashanthan Sanders, Christopher X. Wong Tags: Original Article Source Type: research

Trends in the Use of Warfarin and Novel Oral Anticoagulants in Australia, 2013 to 2017
Background: In 2013, novel oral anticoagulants (NOACs) were added to the PBS as alternatives to warfarin for stroke prevention in atrial fibrillation (AF). Aim of this study is to examine changes in the use of oral anticoagulants (OACs) since the introduction of NOACs.
Source: Heart, Lung and Circulation - June 23, 2019 Category: Cardiology Authors: A. Dina, T. Akindele Tags: 231 Source Type: research

Real World Experience of Direct Oral Anticoagulants with Comparison of Safety Outcomes to the Warfarin Era of Venous Thromboembolism Treatment
Conclusion:This retrospective audit shows that our local safety outcomes are comparable to clinical trials. Low dose anticoagulation and high falls risk (a surrogate marker of frailty) were significant risk factors for both clinically significant bleeding and thrombotic stroke in the DOAC population. These patients are likely frailer with greater co-morbidities and have shared risk factors for bleeding and stroke, suggesting that for these high risk patients, low dose anticoagulation does not negate their risk of complications and careful prescribing and close monitoring remain essential.The sub-comparison between VTE pati...
Source: Blood - November 21, 2018 Category: Hematology Authors: Brook, R., Aswapanyawongse, N., Lim, H. Y., Ho, P. Tags: 331. Pathophysiology of Thrombosis: Poster II Source Type: research

National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the diagnosis and management of atrial fibrillation 2018.
Authors: Brieger D, Amerena J, Attia JR, Bajorek B, Chan KH, Connell C, Freedman B, Ferguson C, Hall T, Haqqani HM, Hendriks J, Hespe CM, Hung J, Kalman JM, Sanders P, Worthington J, Yan T, Zwar NA Abstract INTRODUCTION: Atrial fibrillation (AF) is increasing in prevalence and is associated with significant morbidity and mortality. The optimal diagnostic and treatment strategies for AF are continually evolving and care for patients requires confidence in integrating these new developments into practice. These clinical practice guidelines will assist Australian practitioners in the diagnosis and management of adult ...
Source: Medical Journal of Australia - August 3, 2018 Category: General Medicine Tags: Med J Aust Source Type: research

NOACs Now Mainstream for the Use of Anticoagulation in Non-Valvular Atrial Fibrillation in Australia
The management of stroke risk in patients with non-valvular atrial fibrillation has changed over the past few years. This change has occurred due to the introduction of novel oral anticoagulants (NOACs) such as apixaban, rivaroxaban and dabigatran for the management of non-valvular atrial fibrillation. These agents have shown comparable stroke risk reduction to warfarin in large international multicentre trials [1 –3]. This has changed the clinical practice of many treating physicians since their introduction from 2011 to 2013.
Source: Heart, Lung and Circulation - March 22, 2018 Category: Cardiology Authors: Derk Pol, Claire Curtis, Satish Ramukumar, Logan Bittinger Tags: Brief Communication Source Type: research

NOACs Now Mainstream for the Use of Anticoagulation in Non-Valvular Atrial Fibrillation in Australia.
The management of stroke risk in patients with non-valvular atrial fibrillation has changed over the past few years. This change has occurred due to the introduction of novel oral anticoagulants (NOACs) such as apixaban, rivaroxaban and dabigatran for the management of non-valvular atrial fibrillation. These agents have shown comparable stroke risk reduction to warfarin in large international multicentre trials [1 –3]. This has changed the clinical practice of many treating physicians since their introduction from 2011 to 2013.
Source: Heart, Lung and Circulation - March 22, 2018 Category: Cardiology Authors: Derk Pol, Claire Curtis, Satish Ramukumar, Logan Bittinger Tags: Brief Communication Source Type: research

The impact of non-vitamin K antagonist oral anticoagulants (NOACs) on anticoagulation therapy in rural Australia.
CONCLUSIONS: In rural WA, about one-third of patients with an indication for anticoagulation therapy receive NOACs, but one-third of patients with AF and at risk of stroke received no anticoagulant therapy, and may benefit from NOAC therapy. PMID: 29320668 [PubMed - in process]
Source: Medical Journal of Australia - January 11, 2018 Category: General Medicine Tags: Med J Aust Source Type: research

Dedicated warfarin care programme results in superior warfarin control in Queensland, Australia
ConclusionAustralian warfarin control was good when managed by either GP or WCP, but WCP management increased TTR by 13%. Dedicated warfarin programmes can improve warfarin control and optimise therapy for patients.
Source: International Journal of Clinical Practice - January 9, 2018 Category: Internal Medicine Authors: Nijole Bernaitis, Tony Badrick, Shailendra Anoopkumar ‐Dukie Tags: ORIGINAL PAPER Source Type: research

Anticoagulation knowledge in patients with atrial fibrillation: An Australian survey
ConclusionThe study identified knowledge gaps in patients taking OACs, and these deficiencies appeared to be greater in participants taking DOACs. Knowledge assessment should be integrated into patient counselling sessions to help identify and resolve knowledge deficits.
Source: International Journal of Clinical Practice - January 1, 2018 Category: Internal Medicine Authors: Kehinde O. Obamiro, Leanne Chalmers, Kenneth Lee, Bonnie J. Bereznicki, Luke R. E. Bereznicki Tags: ORIGINAL PAPER Source Type: research

Bleeding-related admissions in patients with atrial fibrillation receiving antithrombotic therapy: results from the Tasmanian Atrial Fibrillation (TAF) study
ConclusionThe overall rate of bleeding in this cohort was low relative to similar observational studies. The rate of major bleeding was higher in patients prescribed warfarin compared to DOACs, with a similar rate of major bleeding for DOACs and antiplatelet agents. Our findings suggest potential to strategies to reduce bleeding include using DOACs in preference to warfarin, and avoiding multiple antithrombotic therapies in patients with AF.
Source: European Journal of Clinical Pharmacology - September 22, 2017 Category: Drugs & Pharmacology Source Type: research

Combining Watchman left atrial appendage closure and catheter ablation for atrial fibrillation: multicentre registry results of feasibility and safety during implant and 30 days follow-up
ConclusionThe outcomes from these international, multicentre registries support the feasibility and safety of performing combined procedures of ablation and Watchman LAAC for patients with non-valvular AF and high stroke risk. Further data are needed on long-term outcomes for the hybrid technique on all-cause stroke and mortality.
Source: Europace - July 3, 2017 Category: Cardiology Source Type: research